BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25514802)

  • 1. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.
    Martin V; Bernasconi B; Merlo E; Balzarini P; Vermi W; Riva A; Chiaravalli AM; Frattini M; Sahnane N; Facchetti F; Mazzucchelli L; Sessa F; Tibiletti MG
    J Thorac Oncol; 2015 Apr; 10(4):595-602. PubMed ID: 25514802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
    Cutz JC; Craddock KJ; Torlakovic E; Brandao G; Carter RF; Bigras G; Deschenes J; Izevbaye I; Xu Z; Greer W; Yatabe Y; Ionescu D; Karsan A; Jung S; Fraser RS; Blumenkrantz M; Lavoie J; Fortin F; Bojarski A; Côté GB; van den Berghe JA; Rashid-Kolvear F; Trotter M; Sekhon HS; Albadine R; Tran-Thanh D; Gorska I; Knoll JH; Xu J; Blencowe B; Iafrate AJ; Hwang DM; Pintilie M; Gaspo R; Couture C; Tsao MS
    J Thorac Oncol; 2014 Sep; 9(9):1255-63. PubMed ID: 25122422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.
    Schildhaus HU; Deml KF; Schmitz K; Meiboom M; Binot E; Hauke S; Merkelbach-Bruse S; Büttner R
    Mod Pathol; 2013 Nov; 26(11):1468-77. PubMed ID: 23743932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
    Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
    Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of immunohistochemistry and fluorescent
    Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
    Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.
    Possidente L; Landriscina M; Patitucci G; Borgia L; Lalinga V; Vita G
    Med Oncol; 2017 May; 34(5):76. PubMed ID: 28364271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
    Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.
    Marchetti A; Pace MV; Di Lorito A; Canarecci S; Felicioni L; D'Antuono T; Liberatore M; Filice G; Guetti L; Mucilli F; Buttitta F
    Lung Cancer; 2016 Sep; 99():11-6. PubMed ID: 27565907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
    Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
    Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
    J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.
    Ilie M; Long E; Butori C; Hofman V; Coelle C; Mauro V; Zahaf K; Marquette CH; Mouroux J; Paterlini-Bréchot P; Hofman P
    Ann Oncol; 2012 Nov; 23(11):2907-2913. PubMed ID: 22735679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
    Trejo Bittar HE; Luvison A; Miller C; Dacic S
    Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.